<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37308249</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>14</Day></DateCompleted><DateRevised><Year>2023</Year><Month>06</Month><Day>27</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2056-5933</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>2</Issue><PubDate><Year>2023</Year><Month>Jun</Month></PubDate></JournalIssue><Title>RMD open</Title><ISOAbbreviation>RMD Open</ISOAbbreviation></Journal><ArticleTitle>Disease modification achievement in patients with lupus nephritis in a real-life setting: mission impossible?</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e003158</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/rmdopen-2023-003158</ELocationID><Abstract><AbstractText Label="OBJECTIVE">A preliminary definition of disease modification (DM) in lupus nephritis (LN) was recently developed focusing on long-term remission and damage prevention, with minimal treatment-associated toxicity. We aimed to further specify aspects of DM criteria in LN, assess DM achievement in a real-world setting and examine potential DM predictors and long-term outcomes.</AbstractText><AbstractText Label="METHODS">We collected clinical/laboratory and histological inception cohort data from biopsy-proven LN patients (82% females) with &#x2265;72 months follow-up at two joint academic centres. Specific criteria for 24-hour proteinuria, estimated glomerular filtration rate (eGFR), renal flares and glucocorticoids dose were set at three time frames (months 0-12, 13-60 and 72) to assess DM. In the first model, DM was achieved if patients fulfilled all four criteria at all three time frames (achievers). In the second model, the continued glucocorticoids reduction criterion was excluded. Logistic regression analyses were performed. Possible different trends in DM achievement between past and recent decades were also investigated.</AbstractText><AbstractText Label="RESULTS">DM was achieved by 60% of patients, increased to 70% when glucocorticoids excluded from DM criteria. 24-hour proteinuria at 9 months predicted DM achievement (OR 0.72, 95% CI 0.53 to 0.97, p=0.03), but none of baseline characteristics. Among patients with &gt;72&#x2009;month follow-up, non-achievers had worse renal outcomes (flares, &gt;30% proteinuria increase, eGFR decline) than achievers at the end of follow-up (median 138 months). Patients diagnosed between 1992 and 2005 were found to have significantly lower percentages of DM achievement and met less often the glucocorticoids dose reduction criterion in all three time frames, compared with those diagnosed between 2006 and 2016 (p=0.006&#x2009;and p&lt;0.01, respectively).</AbstractText><AbstractText Label="CONCLUSIONS">DM was achieved by only 60% of LN patients in a real-life setting, partly due to lack of glucocorticoids dose target attainment, while DM failure was associated with worse long-term renal outcomes. This may imply limitations in the effectiveness or implementation of current LN treatments, supporting the need for novel therapeutic strategies.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Panagiotopoulos</LastName><ForeName>Alexandros</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Rheumatology Unit, First Department of Propaedeutic Internal Medicine, Joint Academic Rheumatology Program, Laiko Hospital, Medical School, National and Kapodistrian University, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Kapsia</LastName><ForeName>Eleni</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Nephrology and Renal Transplantation, Laiko Hospital, Medical School, National and Kapodistrian University, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Michelakis</LastName><ForeName>Ioannis</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0002-3314-3329</Identifier><AffiliationInfo><Affiliation>Medical School, National and Kapodistrian University, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boletis</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Nephrology and Renal Transplantation, Laiko Hospital, Medical School, National and Kapodistrian University, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marinaki</LastName><ForeName>Smaragdi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Nephrology and Renal Transplantation, Laiko Hospital, Medical School, National and Kapodistrian University, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sfikakis</LastName><ForeName>Petros P</ForeName><Initials>PP</Initials><AffiliationInfo><Affiliation>Rheumatology Unit, First Department of Propaedeutic Internal Medicine, Joint Academic Rheumatology Program, Laiko Hospital, Medical School, National and Kapodistrian University, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tektonidou</LastName><ForeName>Maria G</ForeName><Initials>MG</Initials><Identifier Source="ORCID">0000-0003-2238-0975</Identifier><AffiliationInfo><Affiliation>Rheumatology Unit, First Department of Propaedeutic Internal Medicine, Joint Academic Rheumatology Program, Laiko Hospital, Medical School, National and Kapodistrian University, Athens, Greece mtektonidou@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>RMD Open</MedlineTA><NlmUniqueID>101662038</NlmUniqueID><ISSNLinking>2056-5933</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005938">Glucocorticoids</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008181" MajorTopicYN="Y">Lupus Nephritis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005938" MajorTopicYN="N">Glucocorticoids</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007668" MajorTopicYN="N">Kidney</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011507" MajorTopicYN="N">Proteinuria</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">autoimmune diseases</Keyword><Keyword MajorTopicYN="N">lupus erythematosus, systemic</Keyword><Keyword MajorTopicYN="N">lupus nephritis</Keyword></KeywordList><CoiStatement>Competing interests: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>3</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>5</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>14</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>13</Day><Hour>1</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>12</Day><Hour>20</Hour><Minute>52</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37308249</ArticleId><ArticleId IdType="pmc">PMC10277535</ArticleId><ArticleId IdType="doi">10.1136/rmdopen-2023-003158</ArticleId><ArticleId IdType="pii">rmdopen-2023-003158</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hanly JG, O&#x2019;Keeffe AG, Su L, et al. . The frequency and outcome of lupus nephritis: results from an international inception cohort study. Rheumatology (Oxford) 2016;55:252&#x2013;62. 10.1093/rheumatology/kev311</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kev311</ArticleId><ArticleId IdType="pmc">PMC4939728</ArticleId><ArticleId IdType="pubmed">26342222</ArticleId></ArticleIdList></Reference><Reference><Citation>Yap DYH, Tang CSO, Ma MKM, et al. . Survival analysis and causes of mortality in patients with lupus nephritis. Nephrol Dial Transplant 2012;27:3248&#x2013;54. 10.1093/ndt/gfs073</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ndt/gfs073</ArticleId><ArticleId IdType="pubmed">22523116</ArticleId></ArticleIdList></Reference><Reference><Citation>Tektonidou MG, Lewandowski LB, Hu J, et al. . Survival in adults and children with systemic lupus erythematosus: a systematic review and Bayesian meta-analysis of studies from 1950 to 2016. Ann Rheum Dis 2017;76:2009&#x2013;16. 10.1136/annrheumdis-2017-211663</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2017-211663</ArticleId><ArticleId IdType="pubmed">28794077</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri M, Barr E, Magder LS. Risk of renal failure within 10 or 20 years of systemic lupus erythematosus diagnosis. J Rheumatol 2021;48:222&#x2013;7. 10.3899/jrheum.191094</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.191094</ArticleId><ArticleId IdType="pmc">PMC7572868</ArticleId><ArticleId IdType="pubmed">32295853</ArticleId></ArticleIdList></Reference><Reference><Citation>Gatto M, Radice F, Saccon F, et al. . Clinical and histological findings at second but not at first kidney biopsy predict end-stage kidney disease in a large Multicentric cohort of patients with active lupus nephritis. Lupus Sci Med 2022;9:e000689. 10.1136/lupus-2022-000689</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2022-000689</ArticleId><ArticleId IdType="pmc">PMC9109114</ArticleId><ArticleId IdType="pubmed">35568438</ArticleId></ArticleIdList></Reference><Reference><Citation>Kapsia E, Marinaki S, Michelakis I, et al. . Predictors of early response, flares, and long-term adverse renal outcomes in proliferative lupus nephritis: A 100-month median follow-up of an inception cohort. J Clin Med 2022;11:5017. 10.3390/jcm11175017</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm11175017</ArticleId><ArticleId IdType="pmc">PMC9457419</ArticleId><ArticleId IdType="pubmed">36078950</ArticleId></ArticleIdList></Reference><Reference><Citation>Pirson V, Enfrein A, Houssiau FA, et al. . Absence of renal remission portends poor long-term kidney outcome in lupus nephritis. Lupus Sci Med 2021;8:e000533. 10.1136/lupus-2021-000533</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2021-000533</ArticleId><ArticleId IdType="pmc">PMC8395364</ArticleId><ArticleId IdType="pubmed">34446568</ArticleId></ArticleIdList></Reference><Reference><Citation>Moroni G, Gatto M, Tamborini F, et al. . Lack of EULAR/ERA-EDTA response at 1 year predicts poor long-term renal outcome in patients with lupus nephritis. Ann Rheum Dis 2020;79:1077&#x2013;83. 10.1136/annrheumdis-2020-216965</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-216965</ArticleId><ArticleId IdType="pubmed">32503858</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamirou F, Lauwerys BR, Dall&#x2019;Era M, et al. . A proteinuria cut-off level of 0.7 G/day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis: data from the MAINTAIN nephritis trial. Lupus Sci Med 2015;2:e000123. 10.1136/lupus-2015-000123</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2015-000123</ArticleId><ArticleId IdType="pmc">PMC4654096</ArticleId><ArticleId IdType="pubmed">26629352</ArticleId></ArticleIdList></Reference><Reference><Citation>Parikh SV, Nagaraja HN, Hebert L, et al. . Renal flare as a Predictor of incident and progressive CKD in patients with lupus nephritis. Clin J Am Soc Nephrol 2014;9:279&#x2013;84. 10.2215/CJN.05040513</Citation><ArticleIdList><ArticleId IdType="doi">10.2215/CJN.05040513</ArticleId><ArticleId IdType="pmc">PMC3913239</ArticleId><ArticleId IdType="pubmed">24262502</ArticleId></ArticleIdList></Reference><Reference><Citation>Dall&#x2019;Era M, Cisternas MG, Smilek DE, et al. . Predictors of long-term renal outcome in lupus nephritis trials: lessons learned from the Euro-lupus nephritis cohort. Arthritis &amp; Rheumatology 2015;67:1305&#x2013;13. 10.1002/art.39026</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.39026</ArticleId><ArticleId IdType="pubmed">25605554</ArticleId></ArticleIdList></Reference><Reference><Citation>Tektonidou MG, Dasgupta A, Ward MM. Risk of end-stage renal disease in patients with lupus nephritis, 1971-2015: A systematic review and Bayesian meta-analysis. Arthritis &amp; Rheumatology 2016;68:1432&#x2013;41. 10.1002/art.39594</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.39594</ArticleId><ArticleId IdType="pmc">PMC5071782</ArticleId><ArticleId IdType="pubmed">26815601</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu C, Li P, Dang X, et al. . Lupus nephritis: new progress in diagnosis and treatment. J Autoimmun 2022;132:S0896-8411(22)00079-8. 10.1016/j.jaut.2022.102871</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2022.102871</ArticleId><ArticleId IdType="pubmed">35999111</ArticleId></ArticleIdList></Reference><Reference><Citation>Porta SV, Enfrein A, Houssiau F, et al. . Controversies in systemic lupus erythematosus 2021. J Clin Rheumatol 2022;28:229&#x2013;33. 10.1097/RHU.0000000000001859</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/RHU.0000000000001859</ArticleId><ArticleId IdType="pubmed">35616510</ArticleId></ArticleIdList></Reference><Reference><Citation>Mok CC, Teng YKO, Saxena R, et al. . Treatment of lupus nephritis: consensus, evidence and perspectives. Nat Rev Rheumatol 2023;19:227&#x2013;38. 10.1038/s41584-023-00925-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41584-023-00925-5</ArticleId><ArticleId IdType="pubmed">36864291</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanouriakis A, Kostopoulou M, Cheema K, et al. . Update of the joint European League against rheumatism and European renal Association&#x2013;European dialysis and transplant Association (EULAR/ERA&#x2013;EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis 2020;79:713&#x2013;23. 10.1136/annrheumdis-2020-216924</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-216924</ArticleId><ArticleId IdType="pubmed">32220834</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovin BH, Adler SG, Barratt J, et al. . KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney International 2021;100:S1&#x2013;276. 10.1016/j.kint.2021.05.021</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2021.05.021</ArticleId><ArticleId IdType="pubmed">34556256</ArticleId></ArticleIdList></Reference><Reference><Citation>Mok CC. Is treat-to-target in lupus nephritis realistic in clinical practice CRR 2018;15:2&#x2013;6. 10.2174/1573397114666180406100857</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1573397114666180406100857</ArticleId><ArticleId IdType="pubmed">29623845</ArticleId></ArticleIdList></Reference><Reference><Citation>van Vollenhoven RF, Mosca M, Bertsias G, et al. . Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis 2014;73:958&#x2013;67. 10.1136/annrheumdis-2013-205139</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2013-205139</ArticleId><ArticleId IdType="pubmed">24739325</ArticleId></ArticleIdList></Reference><Reference><Citation>Aletaha D, Smolen JS. The definition and measurement of disease modification in inflammatory rheumatic diseases. Rheum Dis Clin North Am 2006;32:9&#x2013;44. 10.1016/j.rdc.2005.09.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rdc.2005.09.005</ArticleId><ArticleId IdType="pubmed">16504819</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagaraja V, Matucci-Cerinic M, Furst DE, et al. . Current and future outlook on disease modification and defining low disease activity in systemic sclerosis. Arthritis Rheumatol 2020;72:1049&#x2013;58. 10.1002/art.41246</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.41246</ArticleId><ArticleId IdType="pmc">PMC7329619</ArticleId><ArticleId IdType="pubmed">32134199</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings J. Disease modification and Neuroprotection in neurodegenerative disorders. Transl Neurodegener 2017;6:25.:25. 10.1186/s40035-017-0096-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40035-017-0096-2</ArticleId><ArticleId IdType="pmc">PMC5613313</ArticleId><ArticleId IdType="pubmed">29021896</ArticleId></ArticleIdList></Reference><Reference><Citation>Halpin DMG, Tashkin DP. Defining disease modification in chronic obstructive pulmonary disease. COPD 2009;6:211&#x2013;25. 10.1080/15412550902918402</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15412550902918402</ArticleId><ArticleId IdType="pmc">PMC2699950</ArticleId><ArticleId IdType="pubmed">19811377</ArticleId></ArticleIdList></Reference><Reference><Citation>van Vollenhoven R, Askanase AD, Bomback AS, et al. . Conceptual framework for defining disease modification in systemic lupus erythematosus: a call for formal criteria. Lupus Sci Med 2022;9:e000634. 10.1136/lupus-2021-000634</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2021-000634</ArticleId><ArticleId IdType="pmc">PMC8961173</ArticleId><ArticleId IdType="pubmed">35346982</ArticleId></ArticleIdList></Reference><Reference><Citation>Houssiau FA. Why will lupus nephritis trials not fail anymore Rheumatology 2016:kew252. 10.1093/rheumatology/kew252</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kew252</ArticleId><ArticleId IdType="pubmed">27338083</ArticleId></ArticleIdList></Reference><Reference><Citation>Aringer M, Costenbader K, Daikh D, et al. . European League against rheumatism/American college of rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol 2019;71:1400&#x2013;12. 10.1002/art.40930</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.40930</ArticleId><ArticleId IdType="pmc">PMC6827566</ArticleId><ArticleId IdType="pubmed">31385462</ArticleId></ArticleIdList></Reference><Reference><Citation>Weening JJ, D&#x2019;Agati VD, Schwartz MM, et al. . The classification of glomerulonephritis in systemic lupus erythematosus Revisited. J Am Soc Nephrol 2004;15:241&#x2013;50. 10.1097/01.asn.0000108969.21691.5d</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.asn.0000108969.21691.5d</ArticleId><ArticleId IdType="pubmed">14747370</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertsias GK, Tektonidou M, Amoura Z, et al. . Joint European League against rheumatism and European renal Association&#x2013;European dialysis and transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and Paediatric lupus nephritis. Ann Rheum Dis 2012;71:1771&#x2013;82. 10.1136/annrheumdis-2012-201940</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2012-201940</ArticleId><ArticleId IdType="pmc">PMC3465859</ArticleId><ArticleId IdType="pubmed">22851469</ArticleId></ArticleIdList></Reference><Reference><Citation>Weeding E, Fava A, Magder L, et al. . One-third of patients with lupus nephritis classified as complete responders continue to accrue progressive renal damage despite resolution of proteinuria. Lupus Sci Med 2022;9:e000684. 10.1136/lupus-2022-000684</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2022-000684</ArticleId><ArticleId IdType="pmc">PMC9047706</ArticleId><ArticleId IdType="pubmed">35512816</ArticleId></ArticleIdList></Reference><Reference><Citation>Anders H-J, Saxena R, Zhao M, et al. . Lupus nephritis. Nat Rev Dis Primers 2020;6:7. 10.1038/s41572-019-0141-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41572-019-0141-9</ArticleId><ArticleId IdType="pubmed">31974366</ArticleId></ArticleIdList></Reference><Reference><Citation>Pakchotanon R, Gladman DD, Su J, et al. . Sustained complete renal remission is a Predictor of reduced mortality, chronic kidney disease and end-stage renal disease in lupus nephritis. Lupus 2018;27:468&#x2013;74. 10.1177/0961203317726376</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203317726376</ArticleId><ArticleId IdType="pubmed">28857717</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidson JE, Fu Q, Ji B, et al. . Renal remission status and longterm renal survival in patients with lupus nephritis: A retrospective cohort analysis. J Rheumatol 2018;45:671&#x2013;7. 10.3899/jrheum.161554</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.161554</ArticleId><ArticleId IdType="pmc">PMC5932209</ArticleId><ArticleId IdType="pubmed">29496892</ArticleId></ArticleIdList></Reference><Reference><Citation>Lichtnekert J, Anders HJ, Lech M. Lupus nephritis: Current perspectives and moving forward. J Inflamm Res 2022;15:6533&#x2013;52. 10.2147/JIR.S363722</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/JIR.S363722</ArticleId><ArticleId IdType="pmc">PMC9726217</ArticleId><ArticleId IdType="pubmed">36483271</ArticleId></ArticleIdList></Reference><Reference><Citation>Obri&#x219;c&#x103; B, Sorohan B, Tu&#x21b;&#x103; L, et al. . Advances in lupus nephritis pathogenesis: from bench to bedside. Int J Mol Sci 2021;22:3766. 10.3390/ijms22073766</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22073766</ArticleId><ArticleId IdType="pmc">PMC8038540</ArticleId><ArticleId IdType="pubmed">33916456</ArticleId></ArticleIdList></Reference><Reference><Citation>Parodis I, Houssiau FA. From sequential to combination and Personalised therapy in lupus nephritis: moving towards a paradigm shift. Ann Rheum Dis 2022;81:15&#x2013;9. 10.1136/annrheumdis-2021-221270</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-221270</ArticleId><ArticleId IdType="pubmed">34521616</ArticleId></ArticleIdList></Reference><Reference><Citation>Furie R, Rovin BH, Houssiau F, et al. . Two-year, randomized, controlled trial of Belimumab in lupus nephritis. N Engl J Med 2020;383:1117&#x2013;28. 10.1056/NEJMoa2001180</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2001180</ArticleId><ArticleId IdType="pubmed">32937045</ArticleId></ArticleIdList></Reference><Reference><Citation>Furie R, Rovin BH, Houssiau F, et al. . Safety and efficacy of Belimumab in patients with lupus nephritis. CJASN 2022;17:1620&#x2013;30. 10.2215/CJN.02520322</Citation><ArticleIdList><ArticleId IdType="doi">10.2215/CJN.02520322</ArticleId><ArticleId IdType="pmc">PMC9718049</ArticleId><ArticleId IdType="pubmed">36302567</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovin BH, Teng YKO, Ginzler EM, et al. . Efficacy and safety of Voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, Multicentre, placebo-controlled, phase 3 trial. Lancet 2021;397:2070&#x2013;80. 10.1016/S0140-6736(21)00578-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)00578-X</ArticleId><ArticleId IdType="pubmed">33971155</ArticleId></ArticleIdList></Reference><Reference><Citation>Aringer M, Alarc&#xf3;n-Riquelme ME, Clowse M, et al. . A glimpse into the future of systemic lupus erythematosus. Ther Adv Musculoskelet Dis 2022;14:1759720X221086719. 10.1177/1759720X221086719</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1759720X221086719</ArticleId><ArticleId IdType="pmc">PMC8972918</ArticleId><ArticleId IdType="pubmed">35368371</ArticleId></ArticleIdList></Reference><Reference><Citation>Yap DYH, Mok CC. Novel and emerging treatment strategies for lupus nephritis. Expert Rev Clin Pharmacol 2022;15:1283&#x2013;92. 10.1080/17512433.2022.2138340</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17512433.2022.2138340</ArticleId><ArticleId IdType="pubmed">36260817</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheung AK, Chang TI, Cushman WC, et al. . KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int 2021;99:559&#x2013;69. 10.1016/j.kint.2020.10.026</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2020.10.026</ArticleId><ArticleId IdType="pubmed">33637203</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossing P, Caramori ML, Chan JCN, et al. . Executive summary of the KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease: an update based on rapidly emerging new evidence. Kidney International 2022;102:990&#x2013;9. 10.1016/j.kint.2022.06.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2022.06.013</ArticleId><ArticleId IdType="pubmed">36272755</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakris G. Are there effects of renin&#x2013;angiotensin system antagonists beyond blood pressure control. Am J Cardiol 2010;105:21A&#x2013;9A. 10.1016/j.amjcard.2009.10.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2009.10.010</ArticleId><ArticleId IdType="pubmed">20102970</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xe4;emann M, Kronbichler A. Call for action in ANCA-associated vasculitis and lupus nephritis: promises and challenges of SGLT-2 inhibitors. Ann Rheum Dis 2022;81:614&#x2013;7. 10.1136/annrheumdis-2021-221474</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-221474</ArticleId><ArticleId IdType="pubmed">34844933</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Li T, Sun F, et al. . Safety and efficacy of the Sglt2 inhibitor Dapagliflozin in patients with systemic lupus erythematosus: a phase I/II trial. RMD Open 2022;8:e002686. 10.1136/rmdopen-2022-002686</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/rmdopen-2022-002686</ArticleId><ArticleId IdType="pmc">PMC9615980</ArticleId><ArticleId IdType="pubmed">36288823</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper Blenkinsopp S, Fu Q, Green Y, et al. . Renal response at 2 years post biopsy to predict long-term renal survival in lupus nephritis: a retrospective analysis of the Hopkins lupus cohort. Lupus Sci Med 2022;9:e000598. 10.1136/lupus-2021-000598</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2021-000598</ArticleId><ArticleId IdType="pmc">PMC9438053</ArticleId><ArticleId IdType="pubmed">36038160</ArticleId></ArticleIdList></Reference><Reference><Citation>Cattran DC, Feehally J, Cook HT. Notice. Kidney International Supplements 2012;2:139. 10.1038/kisup.2012.9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/kisup.2012.9</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbhaiya M, Erkan D, Zuily S, et al. . Characterization of Antiphospholipid antibody-associated nephropathy: an international survey of renal pathology society members - ACR meeting abstracts. Arthritis Rheumatol
2020;72. Available: https://acrabstracts.org/abstract/characterization-of-antiphospholipid-antibody-associated-nephropathy-an-international-survey-of-renal-pathology-society-members/</Citation></Reference><Reference><Citation>Parodis I, Adamichou C, Aydin S, et al. . Per-protocol repeat kidney biopsy portends relapse and long-term outcome in incident cases of proliferative lupus nephritis. Rheumatology 2020;59:3424&#x2013;34. 10.1093/rheumatology/keaa129</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keaa129</ArticleId><ArticleId IdType="pubmed">32353879</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>